State of Wisconsin Investment Board acquired a new position in Acorda Therapeutics, Inc. (NASDAQ:ACOR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 32,000 shares of the biopharmaceutical company’s stock, valued at approximately $630,000. State of Wisconsin Investment Board owned 0.07% of Acorda Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State of Alaska Department of Revenue grew its holdings in shares of Acorda Therapeutics by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 5,120 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 130 shares during the period. Municipal Employees Retirement System of Michigan grew its holdings in shares of Acorda Therapeutics by 3.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 410 shares during the period. Mason Street Advisors LLC grew its holdings in shares of Acorda Therapeutics by 7.7% in the first quarter. Mason Street Advisors LLC now owns 10,852 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 775 shares during the period. Hartford Investment Management Co. bought a new stake in shares of Acorda Therapeutics in the second quarter worth $242,000. Finally, Aperio Group LLC grew its holdings in shares of Acorda Therapeutics by 2.7% in the second quarter. Aperio Group LLC now owns 12,972 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 343 shares during the period.

In other news, Director Barry E. Greene sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $21.57, for a total transaction of $215,700.00. Following the sale, the director now directly owns 10,000 shares in the company, valued at approximately $215,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Scopia Capital Management Lp bought 766,201 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were acquired at an average price of $19.23 per share, for a total transaction of $14,734,045.23. The disclosure for this purchase can be found here. 7.90% of the stock is owned by company insiders.

Several brokerages recently commented on ACOR. BidaskClub lowered Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Cowen and Company reissued an “outperform” rating and set a $35.00 price target on shares of Acorda Therapeutics in a report on Wednesday, June 7th. Cantor Fitzgerald reissued a “hold” rating and set a $18.00 price target on shares of Acorda Therapeutics in a report on Tuesday, August 29th. Janney Montgomery Scott reissued a “hold” rating and set a $18.00 price target on shares of Acorda Therapeutics in a report on Wednesday, August 30th. Finally, J P Morgan Chase & Co set a $24.00 price target on Acorda Therapeutics and gave the company a “hold” rating in a report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $24.36.

ILLEGAL ACTIVITY NOTICE: “State of Wisconsin Investment Board Acquires Shares of 32,000 Acorda Therapeutics, Inc. (ACOR)” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/11/state-of-wisconsin-investment-board-acquires-shares-of-32000-acorda-therapeutics-inc-acor.html.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) opened at 22.80 on Monday. The company’s market cap is $1.06 billion. The stock has a 50 day moving average price of $21.91 and a 200-day moving average price of $20.31. Acorda Therapeutics, Inc. has a 1-year low of $13.60 and a 1-year high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.16. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. The firm had revenue of $139.40 million for the quarter, compared to analysts’ expectations of $139.81 million. During the same period last year, the firm earned $0.07 EPS. The company’s quarterly revenue was up 9.3% on a year-over-year basis. On average, equities research analysts forecast that Acorda Therapeutics, Inc. will post $1.71 EPS for the current year.

Acorda Therapeutics Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.